3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
35
Myelodysplastic Syndromes
28
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Hematologic Neoplasms
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
13
Lymphoma, Non-Hodgkin
12
Myeloproliferative Disorders
11
Lymphoma
11
Leukemia, Myelomonocytic, Chronic
11
Graft vs Host Disease
10
Primary Myelofibrosis
9
Leukemia
9
Hodgkin Disease
9
Leukemia, Lymphocytic, Chronic, B-Cell
7
Anemia, Refractory, with Excess of Blasts
7
Multiple Myeloma
6
Leukemia, Biphenotypic, Acute
6
Burkitt Lymphoma
5
Polycythemia Vera
4
Lymphoma, Follicular
4
Leukemia, Myeloid
4
Leukemia, Lymphoid
4
Anemia, Aplastic
4
Thrombocythemia, Essential
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precancerous Conditions
3
Neoplasms, Plasma Cell
3
Neoplasms
3
Myelodysplastic-Myeloproliferative Diseases
3
Lymphoproliferative Disorders
3
Interventions
Mitomycin
2
tislelizumab
1
molgramostim
1
cryoprecipitate coagulum
1
Tacrolimus
1
Standard of Care
1
Specimen Handling
1
Sirolimus
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Hyperthermic Intraperitoneal Chemotherapy
1
Fluorouracil
1
CTLA-4 Antigen
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pseudomyxoma Peritonei
×
Tacrolimus
×
1 year
×
Clear all
NCT06084780
2026-04-09
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2
Not yet recruiting
20 enrolled